Table 1. Relationships between AXL expression and clinical factors in 161 LAD specimens.
| Factor | AXL expression | P* | |||||
|---|---|---|---|---|---|---|---|
| 0 | 1+ | 2+ | 3+ | ||||
| n | n = 57 | n = 32 | n = 60 | n = 12 | |||
| Sex | Female | 87 | 31 (35%) | 17 (20%) | 33 (38%) | 6 (7%) | 0.77 |
| Male | 74 | 26 (35%) | 15 (20%) | 27 (37%) | 6 (8%) | ||
| Age (years) | < 69 | 82 | 26 (32%) | 20 (24%) | 30 (37%) | 6 (7%) | 0.95 |
| ≥ 69 | 79 | 31 (39%) | 12 (15%) | 30 (38%) | 6 (8%) | ||
| CEA | < 5.0 | 103 | 38 (37%) | 18 (17%) | 41 (40%) | 6 (6%) | 0.25** |
| ≥ 5.0 | 54 | 17 (31%) | 14 (26%) | 17 (31%) | 6 (12%) | ||
| unknown | 4 | 2 (50%) | 0 (0%) | 2 (50%) | 0 (0%) | ||
| P-stage | I | 111 | 40 (36%) | 24 (22%) | 38 (34%) | 9 (8%) | 0.82 |
| II | 25 | 9 (36%) | 3 (12%) | 12 (48%) | 1 (4%) | ||
| III | 23 | 8 (35%) | 5 (22%) | 8 (35%) | 2 (8%) | ||
| IV | 2 | 0 (0%) | 0 (0%) | 2 (100%) | 0 (0%) | ||
| Smoking | Ever | 78 | 27 (35%) | 20 (26%) | 28 (36%) | 3 (3%) | 0.084** |
| Never | 72 | 27 (38%) | 11 (15%) | 26 (36%) | 8 (11%) | ||
| Unknown | 11 | 3 (27%) | 1 (9%) | 6 (55%) | 1 (9%) | ||
| Grade*** | Low | 129 | 44 (34%) | 28 (22%) | 48 (37%) | 9 (7%) | 0.62 |
| High | 31 | 12 (39%) | 4 (13%) | 12 (38%) | 3 (10%) | ||
*[0/1+/2+] vs [3+].
**Patients with unknown status were excluded from statistical analysis.
***One case of minimally invasive adenocarcinoma was excluded. CEA: carcinoembryonic antigen, in μg/L.